iTeos Therapeutics CEO to present at J.P. Morgan Healthcare Conference on January 15, 2025. Live webcast available.
Quiver AI Summary
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology treatments, announced that its CEO, Michel Detheux, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation, scheduled for 7:30 AM PST, will be available via a live webcast on the company's website, with an archived version accessible for about 30 days afterward. iTeos is dedicated to discovering new therapies by targeting tumor immunology and developing clinical programs aimed at overcoming immunosuppression in cancer patients. The company is based in Watertown, MA, with a research facility in Gosselies, Belgium. Investors are encouraged to regularly check the company's website for updates.
Potential Positives
- iTeos Therapeutics will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the biopharmaceutical industry.
- The live webcast of the presentation allows for broader accessibility to investors, potentially increasing investor interest and engagement.
- The company highlights its innovative pipeline, which includes three clinical-stage programs targeting novel immunosuppressive pathways, showcasing its commitment to advancing cancer therapies.
- The press release emphasizes iTeos Therapeutics' expertise in tumor immunology, positioning the company as a leader in the field of immuno-oncology therapeutics.
Potential Negatives
- e
FAQ
What is the date and time of the iTeos Therapeutics presentation?
The presentation is scheduled for January 15, 2025, at 7:30 AM PST (10:30 AM EST).
Where can I watch the iTeos Therapeutics presentation live?
The live webcast will be available on the Investors section of iTeos Therapeutics' website.
What is the focus of iTeos Therapeutics?
iTeos Therapeutics focuses on developing a new generation of immuno-oncology therapeutics for cancer treatment.
How long will the presentation replay be available?
An archived replay of the presentation will be available for approximately 30 days after the event.
What innovative approaches does iTeos Therapeutics use?
The company leverages its understanding of tumor immunology to create novel therapeutics targeting immunosuppressive pathways.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ITOS Insider Trading Activity
$ITOS insiders have traded $ITOS stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ITOS stock by insiders over the last 6 months:
- MATTHEW GALL (Chief Financial Officer) purchased 5,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ITOS Hedge Fund Activity
We have seen 80 institutional investors add shares of $ITOS stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC added 2,407,800 shares (+inf%) to their portfolio in Q3 2024
- ECOR1 CAPITAL, LLC removed 1,641,219 shares (-50.5%) from their portfolio in Q3 2024
- VESTAL POINT CAPITAL, LP removed 725,000 shares (-41.4%) from their portfolio in Q3 2024
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 723,000 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 587,933 shares (-54.0%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 538,927 shares (+77.3%) to their portfolio in Q3 2024
- 683 CAPITAL MANAGEMENT, LLC added 455,288 shares (+40.8%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30 AM EST).
A live webcast of the presentation will be available on the Investors section of the Company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
[email protected]
Media Contact:
[email protected]
